OSE Immunotherapeutics SA (OSE) Stock Statistics & Valuation Metrics

OSE Immunotherapeutics SA has a market cap or net worth of €88.10M. The enterprise value is €112.49M.

OSE Immunotherapeutics SA has 22,680,110 shares outstanding. The number of shares has decreased by -2.65% in one year.

OSE Immunotherapeutics SA’s return on equity (ROE) is -1.38 and return on invested capital (ROIC) is -67.00%.

The current PE Ratio of OSE Immunotherapeutics SA is ―. OSE Immunotherapeutics SA’s PEG ratio is 0.02.

In the last 12 months, OSE Immunotherapeutics SA had revenue of 2.62M and earned -37.70M in profits. Earnings per share was -1.69.

In the last 12 months, operating cash flow was -34.03M and capital expenditures -98.00K, giving a free cash flow of -34.13M billion.

OSE Immunotherapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

OSE Immunotherapeutics SA upcoming earnings date is Sep 28, 2026, During Market Hours (Confirmed).

OSE Immunotherapeutics SA as a current ratio of 1.28, with Debt / Equity ratio of 129.37%

In the past 12 months, OSE Immunotherapeutics SA has paid -4.37M in taxes.

OSE Immunotherapeutics SA EV to EBITDA ratio is -2.96, with an EV/FCF ratio of -3.89.

OSE Immunotherapeutics SA has €22.65M in cash and marketable securities with €35.38M in debt, giving a net cash position of -€12.73M billion.

Gross margin is 0.00%, with operating margin of -1835.01%, and net profit margin of -1439.48%.

The average price target for OSE Immunotherapeutics SA is €8.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy